- Home
- TII vs KZIA Comparison
TII vs KZIA Comparison
Compare TII & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TII | KZIA |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.5M | 186.7M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | TII | KZIA |
|---|---|---|
| Price | $1.90 | $7.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.50 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 230.3K | 229.9K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $4.86 |
| 52 Week High | $5.65 | $17.40 |
Technical Indicators
Market Signals| Indicator | TII | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 30.87 | 37.13 |
| Support Level | $1.89 | $6.72 |
| Resistance Level | $2.47 | $8.18 |
| Average True Range (ATR) | 0.15 | 0.68 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 10.37 | 40.26 |
Price Performance
Historical ComparisonAbout TII Titan Mining Corporation
Titan Mining Corp is a Canadian natural resources company. The company is engaged in the acquisition, exploration, development, and extraction of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States, and Kilbourne Graphite Project. The Company operates one reportable segment, mineral production and exploration in the United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.